Media ReleasesArovella Therapeutics

View All Arovella Therapeutics News

Arovella Therapeutics - Quarterly Appendix 4C and Activities Report

MELBOURNE, AUSTRALIA 29 July 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform for cancer treatment and its oral spray delivery technology to treat cancer and conditions that affect the central nervous system, today released its Appendix 4C for the fourth quarter of FY 2022.

Highlights for the quarter:

-- Q-Gen Service Agreement signed to initiate manufacturing of ALA-101
-- Dr Elizabeth Stoner was appointed as interim Chairperson, and Mr Gary Phillips appointed as a Non-Executive Director
-- Anagrelide patent granted by the US Patent and Trademark Office
-- ZolpiMist launched in Australia by STADA Australia
-- Arovella adopted the WEF Framework for ESG Reporting
-- Quarterly cash burn to reduce now HCBP settled

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.